epcoritamab + ibrutinib + venetoclax

This is a **combination therapy** under clinical investigation for the treatment of chronic lymphocytic leukemia (CLL) and potentially related lymphoid malignancies. The regimen comprises: - **Epcoritamab:** a bispecific monoclonal antibody that targets both CD3 (on T cells) and CD20 (on B cells), facilitating T-cell mediated cytotoxicity of malignant B cells. - **Ibrutinib:** an oral small molecule inhibitor of Bruton's tyrosine kinase (BTK), interrupting B-cell receptor signaling and reducing proliferation and survival of B-cell malignancies. - **Venetoclax:** a selective small molecule inhibitor of BCL-2, promoting apoptosis in malignant B cells. This combination is designed to target malignant B cells with complementary mechanisms: direct immune-mediated cytotoxicity (epcoritamab), inhibition of survival/proliferation pathways (ibrutinib), and induction of apoptosis (venetoclax). Early-phase clinical and preclinical research supports superior cytotoxicity against CLL cells, including in settings with BTKi resistance. It is not an approved regimen but is under clinical investigation, most notably for relapsed/refractory CLL and high-risk cases[1][4][6].

Other names

epcoritamab + ibrutinib + venetoclax